Literature DB >> 22957692

Protective effect of CCR5-Δ32 against HIV infection by the heterosexual mode of transmission in a Polish population.

Katarzyna Zwolińska1, Brygida Knysz, Katarzyna Rybka, Monika Pazgan-Simon, Jacek Gąsiorowski, Maciej Sobczyński, Andrzej Gładysz, Egbert Piasecki.   

Abstract

Effects of chemokine receptor alleles (CCR5-Δ32 and CCR2-64I) on susceptibility to human immunodeficiency virus (HIV) infection were studied in a Polish population. The CCR5 and CCR2 genotypes were determined for 311 healthy, HIV-negative individuals (control group), 121 exposed to HIV infection but uninfected (EU group), and 470 HIV-positive patients. The frequency of the alleles in the control group was calculated as 0.12 for both CCR5-Δ32 and CCR2-64I. The logistic regression method was used to analyze the effects of the described factors. A protective effect was observed for the CCR5-Δ32 allele but only in the case of heterosexual exposure. Prevalence of the CCR5-Δ32/+ genotype in HIV(+) patients infected via the heterosexual route (n=61; 8.2%) was much lower than in the control group (n=311; 21.5%); in the heterosexually exposed uninfected group it was slightly higher (n=28; 25%). This suggested that in this mode of infection, the native CCR5 expression level was crucial for establishment of infection. Individuals with the CCR5-Δ32 allele have more than three times less chance of infection in the case of HIV heterosexual exposure (odds ratio, 3.37; 95% confidence interval, 1.055-10.76). However, a protective effect of the CCR5-Δ32/+ genotype was not observed in the case of intravenous drug users (IDUs). The rates of the genotype were similar in HIV-infected IDU individuals (n=356; 17.7%) and in exposed uninfected patients (n=84; 15.5%), not significantly different from control group. No effect of the CCR2 genotype was observed. The analysis revealed that the important factor increasing infection risk was, in particular, hepatitis C virus (HCV) infection (odds ratio, 12.9). Moreover, the effect of HCV infection was found to be age dependent. Susceptibility to HIV infection resulting from HCV positivity became weaker (6% per year) with increasing age.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22957692     DOI: 10.1089/AID.2011.0362

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Frequency of human endogenous retroviral sequences (HERV) K113 and K115 in the Polish population, and their effect on HIV infection.

Authors:  Katarzyna Zwolińska; Brygida Knysz; Jacek Gąsiorowski; Monika Pazgan-Simon; Andrzej Gładysz; Maciej Sobczyński; Egbert Piasecki
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

Review 2.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

3.  CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects.

Authors:  J A Hubacek; L Dusek; O Majek; V Adamek; T Cervinkova; D Dlouha; J Pavel; V Adamkova
Journal:  Physiol Res       Date:  2021-03-17       Impact factor: 1.881

4.  The effects of killer cell immunoglobulin-like receptor (KIR) genes on susceptibility to HIV-1 infection in the Polish population.

Authors:  Katarzyna Zwolińska; Olga Błachowicz; Tomasz Tomczyk; Brygida Knysz; Jacek Gąsiorowski; Małgorzata Zalewska; Beata U Orzechowska; Marta Sochocka; Egbert Piasecki
Journal:  Immunogenetics       Date:  2016-02-18       Impact factor: 2.846

5.  Identification of Variants of Hepatitis C Virus (HCV) Entry Factors in Patients Highly Exposed to HCV but Remaining Uninfected: An ANRS Case-Control Study.

Authors:  Baptiste Fouquet; Jade Ghosn; Yann Quertainmont; Dominique Salmon; Christophe Rioux; Claudine Duvivier; Jean-François Delfraissy; Micheline Misrahi
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.